

# Treatment of Bronchopleural and Alveolopleural Fistulas in Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation, a Case Series and Literature Review

**OBJECTIVES:** To describe a ventilator and extracorporeal membrane oxygenation management strategy for patients with acute respiratory distress syndrome complicated by bronchopleural and alveolopleural fistula with air leaks.

**DESIGN, SETTING, AND PARTICIPANTS:** Case series from 2019 to 2020. Single tertiary referral center—University of California, San Diego. Four patients with various etiologies of acute respiratory distress syndrome, including influenza, methicillin-resistant *Staphylococcus aureus* pneumonia, e-cigarette or vaping product use-associated lung injury, and coronavirus disease 2019, complicated by bronchopleural and alveolopleural fistula and chest tubes with air leaks.

**MEASUREMENTS AND MAIN RESULTS:** Bronchopleural and alveolopleural fistula closure and survival to discharge. All four patients were placed on extracorporeal membrane oxygenation with ventilator settings even lower than Extracorporeal Life Support Organization guideline recommended ultraprotective lung ventilation. The patients bronchopleural and alveolopleural fistulas closed during extracorporeal membrane oxygenation and minimal ventilatory support. All four patients survived to discharge.

**CONCLUSIONS:** In patients with acute respiratory distress syndrome and bronchopleural and alveolopleural fistula with persistent air leaks, the use of extracorporeal membrane oxygenation to allow for even lower ventilator settings than ultraprotective lung ventilation is safe and feasible to mediate bronchopleural and alveolopleural fistula healing.

**KEY WORDS:** acute respiratory distress syndrome; barotrauma; extracorporeal membrane oxygenation; pneumothorax; thoracostomy

Mazen F. Odish, MD<sup>1</sup>

Jenny Yang, MD<sup>1</sup>

George Cheng, MD, PhD<sup>1</sup>

Cassia Yi, RN, MSN<sup>2</sup>

Eugene Golts, MD<sup>3</sup>

Michael Madani, MD<sup>3</sup>

Travis Pollema, DO<sup>3</sup>

Robert L. Owens, MD<sup>1</sup>

Bronchopleural and alveolopleural fistulas (BAPFs) are exceedingly difficult to treat in patients with acute respiratory distress syndrome (ARDS) on ventilatory support. Approximately 10–30% of ARDS cases are complicated by a BAPF, with 2% having a persistent air leak (PAL) (1, 2). Despite conventional ventilator strategies for ARDS (i.e., low tidal volume [TV] ventilation), increased transpulmonary pressures (TPPs) and high respiratory rates (RRs) may impede closure of a BAPF (2, 3). We describe patients with ARDS and BAPF who were placed on extracorporeal membrane oxygenation (ECMO) to allow for low ventilator pressures that promote BAPF closure.

BAPF are pathologic connections between either the bronchi or alveoli to the pleural space. Differentiating between them can be difficult and both can have a prolonged or PAL defined as an air leak greater than 5 to 7 days (4). PALs

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/CCE.0000000000000393

are associated with longer hospital stays and increased mortality. Bronchopleural fistulas can occur in trauma, post-radiation or microwave ablation, pulmonary infections, or iatrogenic due to pulmonary resections or airway procedures (5). Alveolopleural fistulas etiologies include spontaneous pneumothorax, pulmonary infections such as necrotizing pneumonias, malignancies, iatrogenic after thoracentesis or chest tube placement, and barotrauma from mechanical ventilation. There is considerable overlap in the etiologies of BAPFs and differentiating the cause may be important for therapeutic options. Traditionally bronchopleural fistulas are treated surgically, while alveolopleural fistulas are managed nonoperatively, that is, tube thoracotomy. When positive pressure ventilation is required, the goal is to minimize airway pressures to facilitate BAPF closure (6). Other therapies for refractory BAPF have included surgical repair, endobronchial procedures (endobronchial valves, etc.), and pleurodesis (7). There is considerable variability in the management of BAPFs, depending on the etiology and local expertise.

Conventional ventilator management in ARDS relies on low TV ventilation and plateau pressure goals, which are defined as 6 mL/kg of ideal body weight (IBW) and less than 30 cm H<sub>2</sub>O, respectively. However, this level of ventilatory support may impede BAPF healing due to high TPP. TPP is the distending pressure across the lung (pressure difference from airway opening to pleural space) (8). In the setting of BAPFs, high TPP promotes PALs (9). Thus, decreasing the TPP may help facilitate closure of BAPF.

ECMO is a type of mechanical life support for refractory cardiac and/or respiratory failure (10). This technology has been increasingly used for severe ARDS in the United States since the 2009 H1N1 influenza pandemic and again in 2020 due to the coronavirus disease 2019 (COVID-19) pandemic (11). There is controversy surrounding ventilator management while on ECMO for ARDS. While on ECMO, the Extracorporeal Life Support Organization (ELSO) recommends ultra-protective lung ventilation (UPLV), which is used at the majority of ECMO centers (12). UPLV is defined as positive end-expiratory pressure (PEEP) of 10–15 cm H<sub>2</sub>O, a driving pressure (DP) of 10 cm H<sub>2</sub>O, and RR of 5–10 breaths per minute (13). Depending on the respiratory system compliance, the lower DP results in lower TVs of ~2–4 mL/kg of IBW. Thus, the goal of UPLV supported by ECMO is to lower the TPP further than

low TV ventilation, which will facilitate BAPF closure by decreasing stress across the lung.

We describe our experience in using even lower than UPLV settings in four patients with ARDS and BAPF to allow for further decreases in TPP to promote BAPF closure.

## PATIENTS AND METHODS

This is a retrospective case series from a single tertiary care academic hospital system. Patient records for study inclusion were identified in a previously existing ECMO database from January 1, 2017, to September 30, 2020. Our ECMO database contains data required by the ELSO and is maintained by a group of physician and nurse leaders as part of an institutional quality improvement database. The Institutional Review Board waived the need for informed consent. All patients over the age of 18 years with ARDS who had a BAPF prior to ECMO initiation were included. The primary outcomes were BAPF closure and survival to discharge. Excel 365 (Microsoft, Redmond, WA) was used for data collection and analysis.

## RESULTS

These four patients' demographics, etiology of ARDS and BAPF, and ventilator settings can be seen in **Table 1**. The ventilator settings throughout the patient's hospitalization are found in **Figure 1**. Patient outcomes can be seen in **Table 2**.

### Patient 1

A woman in her late 20s with a history of IV drug abuse presented with fevers and altered mental status and was found to have right internal jugular vein septic thrombophlebitis complicated by methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia, MRSA pneumonia, and ARDS. She was intubated for hypoxic respiratory failure and developed bilateral pneumothoraces for which chest tubes were placed. She also had pneumomediastinum and subcutaneous emphysema with air leaks noted in both chest tubes. The patient was then transferred to our institution with severe ARDS (ratio of Pao<sub>2</sub> to Fio<sub>2</sub> of 96) with a PAL noted from both chest tubes for the preceding 6 days and anuric renal failure. Continuous renal replacement therapy was started using a right femoral dialysis catheter upon arrival. She was also placed on venovenous ECMO with a left femoral

**TABLE 1.**  
**Baseline Characteristics, Illness Etiology and Severity, and Ventilator Settings**

Case	Patient 1		Patient 2		Patient 3		Patient 4	
Age range	Late 20s		Early 20s		Early 30s		Early 50s	
Sex	Female		Male		Female		Male	
Medical history	Illicit drug abuse (methamphetamine and narcotics)		Asthma, vaping		Obesity		Hypertension, polycythemia	
Etiology of bronchopleural and alveolopleural fistula	MRSA pneumonia		E-cigarette or vaping product use-associated lung injury		Influenza, MRSA pneumonia		Coronavirus disease 2019 pneumonia	
Hospital course, complications, and organ dysfunction	Acute renal failure requiring continuous renal replacement therapy		<i>Clostridium difficile</i> colitis, dysphagia		Acute renal failure, MRSA bacteremia, <i>Aspergillus pneumonia</i>		None	
Sequential Organ Failure Assessment score at ICU admission	14		8		9		8	
Pao <sub>2</sub> /Fio <sub>2</sub> ratio pre-ECMO	96		115		88		64	
Pre-/Post-ECMO <sup>a</sup>	Pre	Post	Pre	Post	Pre	Post	Pre	Post
Pao <sub>2</sub>	87	63	66	58	87	97	55	88
Paco <sub>2</sub>	102	43	44	83	55	38	34	41
Respiratory rate	30	12	32	10	30	19	24	10
Tidal volume, mL (mL per kg of ideal body weight)	277 (4.8)	86 (1.5)	300 (3.8)	124 (1.6)	330 (5)	78 (1.2)	370 (6)	70 (1.1)
Positive end-expiratory pressure, cm H <sub>2</sub> O	16	14 <sup>b</sup>	12	5	2	2	6	0
Mean airway pressure, cm H <sub>2</sub> O	23	15	18	7.5	15	5.2	12	1.2
Driving pressure, cm H <sub>2</sub> O	20	8 <sup>b</sup>	13	10	36	10 <sup>b</sup>	21	10 <sup>b</sup>


ECMO = extracorporeal membrane oxygenation, MRSA, methicillin-resistant *Staphylococcus aureus*.

<sup>a</sup>Values pre-ECMO (immediately prior to cannulation); post-ECMO (24 hr postcannulation).

<sup>b</sup>Patient's positive end-expiratory pressure and driving pressure were adjusted while on ECMO, see Figure 1 for day-to-day changes.

21F drainage and left internal jugular 18F reinfusion cannula. Immediate post-ECMO, UPLV was initiated which consisted of: RR from 30 to 12 breaths per minute, DP 20 to 8 cm H<sub>2</sub>O resulting in TV from 277 mL (4.8 mL/kg of IBW) to 87 mL (1.5 mL/kg of IBW), and PEEP from 16 to 14 cm H<sub>2</sub>O. Her PAL resolved after 3 days on ECMO, however, due to intermittent recurrence of air leak, the PEEP was further decreased to 5 and then 0 cm H<sub>2</sub>O

on ECMO days 12 and 17, respectively. Concurrently, DP was decreased to 5 and then 1 cm H<sub>2</sub>O on ECMO days 16 and 17, respectively. With these ventilator settings, which were lower than UPLV (i.e., essentially on T-piece), she required full ECMO support. Three days after these changes, even the intermittent air leak was no longer present. Ventilatory support was gradually increased without recurrent air leak, see Figure 1 for



**Figure 1.** The patient's ventilator settings pre- and post-extracorporeal membrane oxygenation (ECMO). *Bar graphs* and *lines* represent the patient's positive end-expiratory pressure (PEEP) and tidal volumes (TVs), respectively, during hospitalization. The *horizontal black bars* represent driving pressure (DP). Day 0 represents the PEEP and TV 24hr pre-ECMO cannulation. Day 1 represents the ventilator settings immediately post-ECMO cannulation. While on volume cycled ventilation, DP was calculated as end-expiratory plateau pressure minus PEEP. *Star*, date of ECMO decannulation. *Triangle*, last day of chest tube persistent air leak. IBW = ideal body weight.

ventilator management on ECMO. She was weaned off ECMO on day 25 and liberated from the ventilator on day 27. Chest tubes were removed after 35 days, and she was discharged to a long-term acute care (LTAC) facility. Four months later, she returned to visit our ICU and was on room air with no dyspnea.

**Patient 2**

A man in his early 20s with a history of asthma who was actively vaping presented with acute dyspnea and developed respiratory failure requiring mechanical ventilation, with course complicated by right-sided pneumothorax requiring a chest tube that had a continuous air leak. An extensive workup for etiology of his respiratory failure, including infectious, medication-induced, and rheumatologic causes, was negative, so he was diagnosed with e-cigarette, or vaping, product use-associated lung injury (EVALI) (14). The

patient was placed on venovenous ECMO for moderate ARDS (Pao<sub>2</sub>/Fio<sub>2</sub> 115) with barotrauma. He had a 28F bicaval dual-lumen ECMO cannula placed in his left subclavian vein under fluoroscopy guidance. Ventilator changes immediately post-ECMO consisted of: RR from 32 to 10 breaths per minute, DP of 13 to 10 cm H<sub>2</sub>O resulting in TV from 300 mL (3.8 mL/kg of IBW) to 124 mL (1.6 mL/kg of IBW), and PEEP from 12 to 5 cm H<sub>2</sub>O. The pre-ECMO PEEP was already in the UPLV desired range of 10–15 cm H<sub>2</sub>O, thus post-ECMO, the PEEP was specifically titrated even lower to mediate BAPF closure. The patient had a chest tube for 2 days prior to ECMO with a continuous air leak, which resolved immediately upon initiation of ECMO and implementation of UPLV. His pulmonary compliance improved without recurrent air leak, see Figure 1. He tolerated endotracheal intubated and was able to walk around the unit with assistance. After 7 days on ECMO, the patient was decannulated and successfully

**TABLE 2.**  
**Case Series Outcomes**

Case	Patient 1	Patient 2	Patient 3	Patient 4
Total CT days/CT days pre-ECMO/CT days post-ECMO initiation	35/6/29	11/2/9	9/3/6	28/13/15
Time to resolution of air leak	Three d post-ECMO initiation and minimization of ventilator RR, driving pressure, and PEEP <sup>a</sup>	Same day as ECMO initiation and minimization of ventilator RR, TV, and PEEP	Same day as ECMO initiation and minimization of ventilator RR, TV, and PEEP	Same day as ECMO initiation and minimization of ventilator RR, TV, and PEEP
Ventilator days	27	8	20	27 <sup>b</sup>
Tracheostomy (intubation day)	Yes (24)	None	Yes (8)	Yes (24)
ECMO days	25	7	12	16
ECMO complications	None	None	None	None
Length of hospitalization, d <sup>c</sup>	35	12	24	42
Survival to hospital discharge	Yes	Yes	Yes	Yes

CT = chest tube, ECMO = extracorporeal membrane oxygenation, PEEP = positive end-expiratory pressure, RR = respiratory rate, TV = tidal volume.

<sup>a</sup>Patient had a recurrent persistent air leak requiring further decreases in PEEP and TV.

<sup>b</sup>Ventilator days were longer than recorded due to patient being transferred to a long-term acute care while still requiring partial ventilatory support.

<sup>c</sup>Length of hospitalization at our institution; total hospitalization may be longer due to transfer.

extubated the same day, after 8 days on the ventilator. Chest tube was removed after 11 days, and he was discharged home after a 12-day hospitalization.

### Patient 3

An obese woman in her early 30s presented with hypoxic respiratory failure due to influenza with MRSA pneumonia superinfection. Her hospital course was complicated by a right-sided pneumothorax 3 days post-intubation requiring a chest tube. Subsequently, a continuous air leak was noted for 3 days prior to transfer to our center, where she was placed on venovenous ECMO (right femoral 25F drainage and right internal jugular 21F reinfusion cannula) for severe ARDS (Pao<sub>2</sub>/Fio<sub>2</sub> 88) and barotrauma. Ventilator changes post-ECMO consisted

of: RR from 30 to 19 breaths per minute, DP from 36 to 10 cm H<sub>2</sub>O resulting in TV from 330 mL (5 mL/kg of IBW) to 78 mL (1.2 mL/kg of IBW), and PEEP was maintained at 2 cm H<sub>2</sub>O. The continuous air leak immediately resolved with ECMO and lower than UPLV settings (specifically the PEEP). There was gradual improvement of pulmonary compliance without recurrent air leak, see Figure 1, and the chest tube was removed after 11 days. The patient was weaned off ECMO after a total of 12 days and extubated after 20 days, and she was discharged home after a 24-day hospitalization.

### Patient 4

A man in his early 50s with hypertension and polycythemia presented with fevers and cough, and he was

found to have COVID-19 pneumonia. He was intubated for hypoxic respiratory failure and subsequently developed a right-sided pneumothorax with PAL. He was transferred to our center and placed on venovenous ECMO (right femoral 25F drainage and right internal jugular 21F reinfusion cannula) for severe ARDS ( $P_{aO_2}/F_{iO_2}$  64) and barotrauma. Ventilator changes post-ECMO consisted of: RR from 24 to 10 breaths per minute, DP from 21 to 7 cm  $H_2O$  resulting in TV from 370 mL (6 mL/kg of IBW) to 70 mL (1.1 mL/kg of IBW), and PEEP from 6 to 2 cm  $H_2O$ . With these lower than UPLV settings (DP and PEEP) on ECMO, the patient's PAL, which had been present for 13 days, immediately resolved. Ventilatory support was gradually increased without recurrent air leak, see Figure 1. He was decannulated from ECMO after 16 days, and the chest tube was removed the same day. After 27 days on the ventilator, he was able to tolerate intermittent trach collar and was discharged to an LTAC after his 42-day hospitalization.

## DISCUSSION

We present a case series and literature review of patients who have BAPF with ARDS. There are multiple observations: 1) ECMO should be considered in patients with ARDS complicated by BAPF and PALs; 2) a ventilation strategy with even lower PEEP and DP than UPLV (ELSO guidelines) may be used while on ECMO to further decrease TPP and RR to mediate BAPF closure with air leaks (patients 2 and 3), or PALs (patients 1 and 4); and 3) this strategy may apply to multiple etiologies of ARDS and BAPF including EVALI, influenza, COVID-19, and MRSA pneumonia.

ECMO may be considered in patients with severe ARDS and BAPF (15, 16). ECMO support maintains oxygenation and ventilation, allowing clinicians to minimize ventilatory support, which, in addition to tube thoracostomy, can promote healing of BAPFs. While ECMO cannulation strategies are beyond the scope of this case series, we recommend a cannulation strategy that offers maximal flows with minimal recirculation. This strategy usually requires a two-catheter approach—three patients described in our series had a femoral drainage and internal jugular return cannula. Only case 2 had a single site, dual-lumen ECMO cannula (e.g., Crescent [Medtronic, Minneapolis, MN] or Avalon

Elite [Getinge Maquet, Rastatt, Germany]) (17, 18). Single site catheters may be limited due to lower ECMO flows and the need for transesophageal echocardiography or fluoroscopy for cannula placement.

In patients with ARDS and BAPF, ECMO may facilitate closure if used with the appropriate ventilator management that minimizes TPP (i.e., UPLV or lower). This strategy decreases the patient's mean airway pressure and RR. Many ECMO centers use UPLV, similar to the landmark ECMO to Rescue Lung Injury in Severe ARDS study, in an effort to minimize ventilator-induced lung injury (VILI) in ARDS patients (12, 15, 19). Furthermore, decreasing the TPP by reducing the DP may have a mortality benefit in patients with ARDS (9). UPLV can mediate BAPF closure by minimizing air leak that promotes pleural apposition. In three cases (patients 2–4), the air leaks resolved immediately with ventilator settings lower than UPLV as seen in Table 2 and Figure 1. The ventilator settings in these cases were not slowly titrated down but immediately changed post-ECMO cannulation, resulting in the resolution of the air leaks.

However, even with UPLV while on ECMO, some patients may continue to have PAL. This occurred in case 1, who had ongoing air leak while on UPLV. Therefore, we further minimized TPP with a DP of 1 cm  $H_2O$  and PEEP of 0 cm  $H_2O$ , which led to resolution of the air leak. After 3 days, we then challenged the lung with increasing PEEP to see if the air leak would reoccur. In these scenarios, the further decrease in the TPP likely promoted BAPF healing. Additionally, due to the efficiency of ECMO to remove carbon dioxide, the RR can be decreased to 5–10 breaths per minute to further facilitate BAPF closure. This strategy may also further minimize VILI through the decrease in cyclical lung strain with each ventilated breath (19). We acknowledge that some levels of PEEP may be protective against VILI in patients with ARDS by preventing atelectatic trauma and thus superinfections (20, 21). Although there is a paucity of data on long-term outcomes, we believe our strategy offers a pragmatic approach to BAPF treatment.

In some centers, after ECMO initiation, an early tracheostomy is performed, or the patient is extubated, so that they may be quickly weaned off sedation and mechanical ventilation. This strategy minimizes or eliminates the need for positive pressure ventilation that will decrease TPP. Our center does not routinely perform early tracheostomies for ARDS and the

decision is made on a case-by-case basis. For example, case 2 did not undergo tracheostomy as it was believed he might recover quickly, and he was still able to participate in physical therapy and other care even with an endotracheal tube in place. However, we note that TPP might still be high (even off of positive pressure ventilation) depending on respiratory drive and the patient's negative intrathoracic pressure during inspiration. Those who are delirious or have ARDS with very poor lung compliance may have persistently high RR/drive. For example, Crotti et al (22) showed that increases in ECMO gas sweep could effectively reduce RR and drive in those ECMO patients with chronic obstructive pulmonary disease or bridge to transplant, but not uniformly in those with ARDS. Thus, we believe minimizing time on positive pressure ventilation (with or without tracheostomy) may help mediate

BAPF closure in select patients if their respiratory patterns (as a surrogate for TPP) and BAPF are closely monitored.

To our knowledge, there are no prior reports utilizing our ventilator strategy in medical (i.e., nonsurgical) patients with ARDS and BAPF. There is limited literature utilizing ECMO for patients with traumatic or surgical bronchopleural fistulas, which are summarized in **Table 3** (23–27). Similar to our cohort, ventilator settings were minimized post-ECMO to promote bronchopleural fistula closure. However, these studies have three notable differences. First, our population consists of patients with ARDS, while these studies only included patients with surgical complications resulting in bronchopleural fistulas. Second, the patients in these surgical case series required interventions to repair their BAPFs. Finally, we used venovenous ECMO

**TABLE 3.**  
**Previous Case Reports and Series With Bronchopleural Fistulas Treated With Extracorporeal Life Support**

References	Etiology of Bronchopleural Fistulas	Ventilator Strategies Post-Extracorporeal Life Support	Survival to Discharge/ Total (%)	Other Notes
Grant et al (23)	Gunshot wounds, motor vehicle accident	RR 6–7 beats/min, TV $\leq$ 4 mL/kg of IBW, PEEP $\leq$ 10 cm H <sub>2</sub> O, goal PIP 30 cm H <sub>2</sub> O, and plateau pressure $<$ 25 cm H <sub>2</sub> O	3/3 (100)	ICU days: 84, 175, and 80 d ECMO days: 24, 20, and 16
Khan et al (24)	Lung transplant in cystic fibrosis patient	RR 12 beats/min, driving pressure 18 mm Hg, and PEEP 2 mm Hg	1/1 (100)	Two cm fistula in donor right main stem bronchus closed with a pericardial and intercostal pedicle flap
Daoud et al (26)	Lung transplant, lobectomies, and esophagectomies	RR $\leq$ 10 beats/min, TV $\leq$ 4 mL/kg of IBW, PEEP $\leq$ 5 cm H <sub>2</sub> O, goal PIP 30 cm H <sub>2</sub> O, and FiO <sub>2</sub> $\leq$ 0.6	2/5 (40)	All were placed on venoarterial ECMO
Hommel et al (25)	Pneumonectomy, lobectomy, trauma, and esophageal resection	TV $\leq$ 4 mL/kg of IBW and PEEP not titrated	4/4 (100)	Treated with pumpless extracorporeal carbon dioxide removal. Two were treated with surgical repair and the other two with fibrin
Dünser et al (27)	Pneumonectomy	Airway pressure release ventilation, peak pressure 25 mbar, PEEP 12 mbar, inspiratory time 1.7 s, expiratory time 0.5 seconds, and FiO <sub>2</sub> 1.0	1/1 (100)	Surgical repair with ECMO support


beats/min = breaths per minute, ECMO = extracorporeal membrane oxygenation, IBW = ideal body weight, PEEP = positive end-expiratory pressure, PIP = peak inspiratory pressure, RR = respiratory rate, TV = tidal volume.

for all our patients, while some patients in these series were placed on extracorporeal carbon dioxide removal or venoarterial ECMO.

The standard therapy for BAPF with air leaks may not apply in patients with ARDS; thus, we have recommended the following algorithm in **Figure 2**. Therapies for PALs such as endobronchial valves, stents, and surgical repair may not be tolerated in patients with ARDS due to their high oxygenation and ventilation requirements. Endobronchial valve placement may not be feasible as multiple lobes may be affected by BAPFs since ARDS causes diffuse lung injury. Furthermore, these patients may not tolerate neither the sequential balloon occlusion necessary to determine optimal endobronchial valve location nor having a lung segment unable to participate in gas exchange postvalve placement (28). However, during ECMO

support, these therapies may be better tolerated. Only in case 1 were endobronchial valves considered; however, we decided to pursue a trial of very low TPP before attempting placement of a valve. Cases 2–4 did not have endobronchial valves considered due to the quick resolution of the BAPF post-ECMO and implementation of UPLV or lower. Case 4 was also not considered a candidate due to the concerns for staff exposure to COVID-19 during the procedure. Finally, use of blood patches for BAPF in patients with ARDS may not be feasible or safe since these critically ill patients often have a baseline low hemoglobin and would poorly tolerate infectious complications.

There are many unanswered questions. Importantly, the optimal PEEP, DP, and resulting TPP in patients with ARDS on ECMO is currently unknown. Because TPP includes spontaneous respiratory efforts, it may



**Figure 2.** Algorithm for treatment of mechanically ventilated patients with acute respiratory distress syndrome (ARDS) and bronchopleural and alveolopleural fistulas (BAPFs). DP = driving pressure, ECMO = extracorporeal membrane oxygenation, PAL = persistent air leak, PEEP = positive end-expiratory pressure, RR = respiratory rate, TPP = transpulmonary pressure.



be important to also reduce spontaneous respiratory drive with sedation or even neuromuscular blockade while providing full ECMO support. Substantial respiratory drive that increases TPP may be a limiting factor to early extubation (with or without tracheostomy) while on ECMO support. We further have little evidence to guide our duration of UPLV (or even lower ventilator settings as in our cases) with low TPP, when to rechallenge the lung with higher TPP, and the long-term outcomes in these patients. Longer courses of UPLV increase the inherent risks associated with mechanical ventilation and ECMO support, such as ventilator-associated pneumonia and bleeding. Importantly, in our series, the decision to place patients on ECMO were based not solely on presence of BAPF but also the severity of ARDS. Again, the risks and benefits of this approach have not been delineated. Further rigorous research in this area is needed, both small physiologic studies carefully measuring TPP as well as larger multicenter studies of ventilator management comparing hard outcomes.

## CONCLUSIONS

In patients with ARDS, ECMO and standard UPLV can be used to promote closure of BAPF. However, even with UPLV, there are select cases with refractory PALs in which further decreases in TPP (DP and PEEP) and RR could be considered.

## ACKNOWLEDGMENTS

We thank the extracorporeal membrane oxygenation (ECMO) team at our institution including physicians, ICU nurses, perfusionists, nurse-ECMO specialists, pharmacists, respiratory therapists, social workers, palliative care providers, and physical and occupational therapists.

- 1 Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, UC San Diego, La Jolla, CA.
- 2 Department of Nursing, UC San Diego Health, La Jolla, CA.
- 3 Department of Surgery, Division of Cardiovascular and Thoracic Surgery, UC San Diego, La Jolla, CA.

Dr. Odish is currently receiving a grant (T32GM121318) from National Institute of General Medical Sciences and National Institutes of Health (NIH). Dr. Owens is currently receiving a grant (R01HL142114) from National Heart, Lung, and Blood

Institute and NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: modish@health.ucsd.edu

## REFERENCES

1. Soma K: Acute respiratory distress syndrome and pneumothorax. *Japanese J Anesthesiol* 2013; 62:547–556
2. Brower RG, Matthay MA, Morris A, et al: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342:1301–1308
3. Thompson BT, Chambers RC, Liu KD: Acute respiratory distress syndrome. *N Engl J Med* 2017; 377:562–572
4. Dugan KC, Laxmanan B, Murgu S, et al: Management of persistent air leaks. *Chest* 2017; 152:417–423
5. Okuda M, Go T, Yokomise H: Risk factor of bronchopleural fistula after general thoracic surgery: Review article. *Gen Thorac Cardiovasc Surg* 2017; 65:679–685
6. Doelken P, Sahn S: Pleural disease in the critically ill patient. *In: Intensive Care Medicine*. Sixth Edition. Irwin RS, Rippe JM (Eds). Philadelphia, PA, Lippincott, Williams, and Wilkins, 2008, p 636
7. Sakata KK, Reisenauer JS, Kern RM, et al: Persistent air leak - review. *Respir Med* 2018; 137:213–218
8. Loring SH, Topulos GP, Hubmayr RD: Transpulmonary pressure: The importance of precise definitions and limiting assumptions. *Am J Respir Crit Care Med* 2016; 194:1452–1457
9. Amato MB, Meade MO, Slutsky AS, et al: Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015; 372:747–755
10. Brodie D, Slutsky AS, Combes A: Extracorporeal life support for adults with respiratory failure and related indications: A review. *JAMA* 2019; 322:557–568
11. Davies AR, Jones D, Bailey M, et al: Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. *JAMA* 2009; 302:1888
12. Schmidt M, Pham T, Arcadipane A, et al: Mechanical ventilation management during ECMO for ARDS: An international multicenter prospective cohort. *Am J Respir Crit Care Med* 2019; 200:1002–1012
13. ELSO Adult Respiratory Failure Guidelines Extracorporeal Life Support Organization (ELSO) Guidelines for Adult Respiratory Failure ELSO Adult Respiratory Failure Guidelines. 2017. Available at: [www.elseo.org](http://www.elseo.org). Accessed May 20, 2020
14. Siegel DA, Jatlaoui TC, Koumans EH, et al; Lung Injury Response Clinical Working Group; Lung Injury Response Epidemiology/Surveillance Group: Update: Interim guidance for health care providers evaluating and caring for patients with suspected E-cigarette, or vaping, product use associated

- lung injury - United States, October 2019. *MMWR Morb Mortal Wkly Rep* 2019; 68:919–927
15. Combes A, Hajage D, Capellier G, et al; EOLIA Trial Group, REVA, and ECMONet: Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 2018; 378:1965–1975
  16. Schmidt M, Bailey M, Sheldrake J, et al: Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. *Am J Respir Crit Care Med* 2014; 189:1374–1382
  17. Getinge: Avalon Elite Bi-Caval Dual Lumen Catheter. 2020. Available at: <https://www.getinge.com/en-ca/product-catalog/avalon-elite-bi-caval-dual-lumen-catheter/>. Accessed May 31, 2020
  18. MC3 Cardiopulmonary: Crescent™ Jugular Dual Lumen Catheter. 2020. Available at: <https://www.mc3corp.com/crescent>. Accessed May 31, 2020
  19. Finfer SR, Vincent JL, Slutsky AS, et al: Critical care medicine ventilator-induced lung injury. *N Engl J Med* 2013; 22369:2126–2136
  20. Beitler JR, Sarge T, Banner-Goodspeed VM, et al: Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio<sub>2</sub> strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: A randomized clinical trial. *JAMA*. 2019; 321:846–857
  21. Brower RG, Lanken PN, MacIntyre N, et al; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 2004; 351:327–336
  22. Crotti S, Bottino N, Ruggeri GM, et al: Spontaneous breathing during extracorporeal membrane oxygenation in acute respiratory failure. *Anesthesiology* 2017; 126:678–687
  23. Grant AA, Lineen EB, Klima A, et al: Refractory traumatic bronchopleural fistula: Is extracorporeal membrane oxygenation the new gold standard? *J Card Surg* 2020; 35:242–245
  24. Khan NU, Al-Aloul M, Khasati N, et al: Extracorporeal membrane oxygenator as a bridge to successful surgical repair of bronchopleural fistula following bilateral sequential lung transplantation: A case report and review of literature. *J Cardiothorac Surg* 2007; 2:28
  25. Hommel M, Deja M, von Dossow V, et al: Bronchial fistulae in ARDS patients: Management with an extracorporeal lung assist device. *Eur Respir J* 2008; 32:1652–1655
  26. Daoud O, Augustin P, Mordant P, et al: Extracorporeal membrane oxygenation in 5 patients with bronchial fistula with severe acute lung injury. *Ann Thorac Surg* 2011; 92:327–330
  27. Dünser M, Hasibeder W, Rieger M, et al: Successful therapy of severe pneumonia-associated ARDS after pneumonectomy with ECMO and steroids. *Ann Thorac Surg* 2004; 78:335–337
  28. Ding M, Gao YD, Zeng XT, et al: Endobronchial one-way valves for treatment of persistent air leaks: A systematic review. *Respir Res* 2017; 18:186